Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Mentor: Santa Barbara, Calif. firm completes three-year syndicated credit agreement providing up to $200 mil. for pursuit of "licensing and acquisition opportunities" in markets where Mentor already competes, President & CEO Joshua Levine says. Bank of the West and Union Bank of California sponsored the agreement, which provides the option for a $50 mil. increase in the future. Separately, Mentor plans to launch its Hyalite non-animal stabilized hyaluronic acid, which it acquired through its 2003 purchase of A-life, in early 2006 (1"The Gray Sheet" May 30, 2005, p. 19). Hyalite will compete against Inamed's Hylaform avian-derived and Captique non-animal fillers, and Medicis' non-animal Restylane...

You may also be interested in...



Facial Aesthetics Line To Help Mentor Keep Up With Medicis/Inamed

Mentor plans to compete with Inamed in the hyaluronic acid (HA) dermal filler market, following an expected PMA approval of its Hyalite non-animal stabilized HA filler early 2006

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel